-

CMP Scientific's Cutting-Edge Technology Solves CE-SDS Peak Identification Challenge

BROOKLYN, N.Y.--(BUSINESS WIRE)--CMP Scientific Corp., a leading innovator in advancing biotech analysis, has unveiled a groundbreaking method that addresses a longstanding challenge in the biotechnology industry: the accurate identification of CE-SDS peaks, essential for assessing the purity and quality of antibody therapeutics. By integrating the power of capillary zone electrophoresis-mass spectrometry (CZE-MS) with CE-SDS assays, CMP Scientific has set a new benchmark for precision, speed, and efficiency in impurity detection.

  • CMP's Technological Edge: The novel method developed by CMP Scientific excels in its ability to rapidly and accurately identify impurities in antibody production, a task that has historically been challenging and time-consuming.
  • Overcoming CE-SDS Challenges: This innovative approach has successfully addressed key difficulties in CE-SDS peak identification, providing a robust and efficient solution that simplifies the process and enhances reliability.
  • High-Resolution Separation: Leveraging the unmatched power of CZE-MS, CMP Scientific's method ensures that even trace impurities are detected and characterized with exceptional clarity and accuracy.
  • Comprehensive Solution: The method offers a holistic solution, applicable across various stages of biopharmaceutical development, from discovery to final product quality control.
  • Synergistic Approach: Combining CZE-MS and CE-SDS assays enhances detection capabilities, offering complementary insights for more comprehensive impurity profiling in antibody therapeutics.

Quote from Dr. James Xia, CEO of CMP Scientific:

"At CMP Scientific, we are committed to pushing the boundaries of what's possible in biotech analysis. Our latest breakthrough is a testament to our innovative spirit and technical prowess, offering a revolutionary solution for the accurate identification of CE-SDS peaks, which are crucial for ensuring the quality and safety of antibody therapeutics."

For more detailed information about this innovative method, please refer to the peer-reviewed article co-authored with our industry partners in a leading scientific journal. You can access the full text of the publication through the following link: https://rdcu.be/dSvhM

About CMP Scientific

CMP Scientific specializes in capillary electrophoresis coupled with electrospray mass spectrometry (CE-MS) products and technologies. The company's product portfolio includes CE-MS systems, CE-MS ion sources, CE instruments, separation capillaries, electrospray emitters, cIEF-MS reagent kits, and peripheral equipment. CMP Scientific's globally patented EMASS-II CE-MS coupling technology is recognized for its exceptional stability, sensitivity, and performance.

For more information, please visit www.cmpscientific.com.

Contacts

Joshua Wiley, PhD
Director of R&D
CMP Scientific Corp
+1 530-387-4198
Joshua.wiley@cmpscientific.com

CMP Scientific Corp.


Release Versions

Contacts

Joshua Wiley, PhD
Director of R&D
CMP Scientific Corp
+1 530-387-4198
Joshua.wiley@cmpscientific.com

More News From CMP Scientific Corp.

CMP Scientific Launches BioSummit™ CVA System, the Next-Generation cIEF-MS Platform for Charge Variant Analysis

BROOKLYN, N.Y.--(BUSINESS WIRE)--CMP Scientific, a leader in capillary electrophoresis-mass spectrometry (CE-MS) technologies, is proud to announce the launch of its highly anticipated BioSummit™ CVA system at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics. This state-of-the-art technology is set to revolutionize online charge variant analysis of recombinant protein therapeutics, offering unparalleled precision and robustness for capillary zone electrophoresis-mass spectrometry...

CMP Scientific Signs a Co-Marketing Agreement with Agilent to Advance Capillary Electrophoresis–Mass Spectrometry Solutions

BROOKLYN, N.Y.--(BUSINESS WIRE)--CMP Scientific, a leader in Capillary Electrophoresis-Mass Spectrometry (CE-MS) technologies, signed a global co-marketing agreement with Agilent....
Back to Newsroom